Hans Moebius
Direttore Tecnico/Scientifico/R&S presso Exciva GmbH
Patrimonio netto: 239 683 $ in data 31/05/2024
Posizioni attive di Hans Moebius
Società | Posizione | Inizio | Fine |
---|---|---|---|
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Direttore Tecnico/Scientifico/R&S | 01/04/2020 | - |
Storia della carriera di Hans Moebius
Precedenti posizioni note di Hans Moebius
Società | Posizione | Inizio | Fine |
---|---|---|---|
ATHIRA PHARMA, INC. | Direttore Tecnico/Scientifico/R&S | 01/04/2019 | 05/01/2024 |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Amministratore Delegato | 01/01/2016 | 01/01/2019 |
Direttore Tecnico/Scientifico/R&S | 01/01/2016 | 01/01/2019 | |
Fondatore | 01/01/2016 | 01/01/2019 | |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/12/2016 | 01/04/2018 |
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Direttore Tecnico/Scientifico/R&S | - | 01/01/2016 |
Formazione di Hans Moebius
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Technische Universität Kaiserslautern | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Germania | 4 |
Posizioni
Chief Tech/Sci/R&D Officer | 5 |
Chief Executive Officer | 1 |
Founder | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ATHIRA PHARMA, INC. | Health Technology |
Aziende private | 3 |
---|---|
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Health Technology |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Commercial Services |
- Borsa valori
- Insiders
- Hans Moebius
- Esperienza